Phase 3 monotherapy results A post-hoc analysis of the phase 3 data showed cagrilintide 2.4 mg monotherapy produced 11.8% average body weight reduction versus 2.3% for placebo over 68 weeks
WADA Prohibition The World Anti-Doping Agency classifies both peptides as prohibited substances: Both listed under Section S0 (Non-Approved Substances) Prohibited at all times (in and out of competition) No Therapeutic Use Exemptions (TUEs) available for either peptide Detection methods under development for anti-doping testing TB-500 and thymosin beta-4 explicitly banned since 2011 WADAs position reflects that neither peptide has regulatory approval from any health authority worldwide
This guide explains what Epithalon is, how it is proposed to work, what it may support, who is a candidate, how it is administered, and what is honestly known about its safety
FAQs What are the different types of nutritional supplements manufactured by your company
*The results described in these testimonials may not be typical
0.25 to 0.5 mg daily, subcutaneous near injury 2.5 mg twice weekly (5 mg total) for weeks 1-4 2.0 to 2.5 mg weekly for weeks 5-8 6 to 8 weeks total Use separate vials and syringes
